Government tenders & NUPCO, the procurement playbook.
Almost all public-sector pharma in Saudi Arabia is bought by one company — NUPCO, on behalf of the Ministry of Health and the wider government health system. This is the whole game: who buys, the tender cycle end to end, the SFDA-registration gate you can't bid without, and the local-content price preference that can reach ~30%.
The procurement map
Public-sector pharma in Saudi Arabia flows through one aggregator and a handful of end customers. Know which box your buyer sits in — it decides the route, the rules and who you sell to.
- Fully owned by the Public Investment Fund (PIF); founded 2009
- Procures & distributes medicines, devices and supplies for government health
- Runs the e-procurement portal: supplier registration, tenders, unified e-catalogue
- Ministry of Health hospitals and primary-care centers
- Ministry of National Guard Health Affairs + Ministry of Interior medical services
- University & specialized hospitals and medical cities
- Health clusters deliver care across primary, secondary & tertiary networks
- The Health Holding Company owns and manages the clusters
- MOH shifts toward oversight, regulation and purchasing/financing
- Military & security medical services increasingly route via the unified system
- Private hospitals, polyclinics and retail pharmacy buy commercially (not via NUPCO)
- General (non-health) government buying runs on the Etimad portal under the GTPL
On the framework vs shut out
Winning a NUPCO framework is a binary. Either you are on the agreement and eligible for national call-offs, or the public-sector volume is simply closed to you. Here is what changes either way.
| Dimension | On a NUPCO framework | Shut out |
|---|---|---|
| Access to the volume | On the framework — eligible for national call-offs across the public network | No route to public-sector volume; private channel only |
| Revenue visibility | Multi-year supply framework with volume commitments | Transactional, order-by-order at best |
| Prerequisite | Valid SFDA marketing authorization in place before you can bid | Cannot enter the tender at all without it |
| Eligibility to contract the state | Regional HQ in Saudi (required for government contracts since 1 Jan 2024) | No RHQ → barred from government contracts |
| Price competitiveness | Local content can earn up to +30% price preference in evaluation | Foreign-only bid scored without the local-content edge |
| Market signal | A committed national supply partner | An opportunistic importer |
The prerequisites
The tender is not the start line — it is the finish of a readiness checklist. Miss one of these and the bid never opens. The first is non-negotiable.
From registration to call-offs
The full loop, end to end. Steps marked gate are the ones that actually decide whether you bid and whether you win — the SFDA marketing authorization above all.
Register the company on NUPCO's e-procurement portal and complete prequalification. Foreign manufacturers also need their SFDA product registration and a local agent / MOC registration in place.
Hold a valid SFDA registration for each product — the hard prerequisite to bid. This is the long pole; start it months before the tender.
Public health facilities submit their needs on a scheduled plan; NUPCO consolidates demand and runs the main national tender (reported annually, in Q1), inviting registered suppliers by category via the e-system.
Submit the bid: a technical offer (specifications, registration, quality) and a financial offer (price), in line with the Government Tenders & Procurement Law process.
Bids are opened and evaluated. The GCC / national-product price preference is applied — national products get a notional price advantage, with an extra pharma preference for listed products and domestic API.
NUPCO awards multi-year supply framework agreements to the successful suppliers — the mechanism the GTPL sets out for repeated, shared procurement.
Facilities draw down against the framework through call-off orders; NUPCO handles the logistics, warehousing and distribution across the network.
The binding constraint is your SFDA marketing authorization — without it you cannot bid, and it takes months. The procurement itself centers on a large annual tender (reported in Q1), and the reward is a multi-year framework that facilities then draw against. Tender calendars and validity periods vary by category — confirm dates on the NUPCO portal (S2 · S12 · S13).
The price preference that can reach ~30%
The single biggest controllable advantage in evaluation. National products get a notional price edge — and pharma gets an extra layer for listed products and domestic active ingredient. It can move a losing bid into the money.
A 'price preference' is a notional discount applied to a national bid during evaluation — it does not change the price you are paid, it changes how your price is scored against rivals. The base national-product preference is set in the MOF local-content regulations (up to 10%, S7). LCGPA added a pharma-sector mechanism (reported 6 Feb 2025) granting up to a further 20% — up to 10% for being on the list and up to 10% for domestic API — taking the ceiling toward ~30%. A valid SFDA registration is required (S11). Treat the exact stacking as directional and confirm against the current LCGPA mechanism before relying on it.
The readiness playbook
Five moves that decide the round — sequenced the way a market-access team should run them, backwards from the tender date.
Should you chase the tender?
One readiness test decides it: is the product registered (or nearly), and can you tell a local-content story?
- Lock the SFDA MA and prequalify early
- Pursue the local-content price preference
- Stand up the RHQ + a reliable supply partner
- No SFDA MA = no bid — start registration now
- Weigh a local partner / technology transfer
- Until then, the private channel is the realistic route
The pharma & RaqibHealth angle
NUPCO is the biggest single buyer in the market, and the gate to it is the SFDA register. Tender-readiness is, at its core, a registration-intelligence problem.
Where every figure comes from
Official primary sources (NUPCO, the Ministry of Finance, LCGPA, PIF and Vision 2030) are marked in green. The annual-cycle timing, the prequalification mechanics and the precise preference stacking are carried by advisories / press and flagged for verification — confirm them on the NUPCO and LCGPA portals before you rely on them.
This guide is informational and not legal, regulatory or tax advice. Saudi government-procurement rules, NUPCO tender calendars, prequalification requirements and local-content preference mechanisms change frequently — always confirm against the official NUPCO, Etimad, Ministry of Finance and LCGPA sources, and take qualified Saudi legal/regulatory advice, before bidding. RaqibHealth cites SFDA on every record. info@raqibhealth.com · RaqibHealth home